Abstract
Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochemical activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. M2698 is kinase selective, possesses favorable physical, chemical, and DMPK profiles, is orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.
MeSH terms
-
Animals
-
Cell Line, Tumor
-
High-Throughput Screening Assays
-
Humans
-
Neoplasms* / drug therapy
-
Neoplasms* / enzymology
-
Neoplasms* / metabolism
-
Phosphatidylinositol 3-Kinases / drug effects
-
Protein Kinase Inhibitors* / pharmacology
-
Protein Kinase Inhibitors* / therapeutic use
-
Proto-Oncogene Proteins c-akt* / antagonists & inhibitors
-
Proto-Oncogene Proteins c-akt* / metabolism
-
Ribosomal Protein S6 Kinases, 70-kDa* / antagonists & inhibitors
-
Ribosomal Protein S6 Kinases, 70-kDa* / metabolism
-
Signal Transduction / drug effects
-
Stereoisomerism
-
Structure-Activity Relationship
-
TOR Serine-Threonine Kinases / drug effects
Substances
-
MTOR protein, human
-
Phosphatidylinositol 3-Kinases
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins c-akt
-
Ribosomal Protein S6 Kinases, 70-kDa
-
TOR Serine-Threonine Kinases
-
M2698